Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.

Biomolecules - 17 Jul 2022

Bokharaie Honey, Kolch Walter, Krstic Aleksandar

Abstract excerpt

Alternative mRNA splicing is common in cancers. In BRAF V600E-mutated malignant melanoma, a frequent mechanism of acquired resistance to BRAF inhibitors involves alternative splicing (AS) of BRAF. The resulting shortened BRAF protein constitutively dimerizes and conveys drug resistance. Here, we have analysed AS in SK-MEL-239 melanoma cells and a BRAF inhibitor (vemurafenib)-resistant derivative that expresses an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alternative Splicing
Share to Drug Resistance, Neoplasm
Share to Indoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Sulfonamides

Share to Vemurafenib

Source

Open in PubMed Open full text

Identifiers

PMID: 35883549
DOI: 10.3390/biom12070993
PMCID: PMC9312936

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of Alternative mRNA Splicing in Vemurafenib-Resistant Melanoma Cells.PMID 35883549Read ↗

Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicingSemantic proximity Read ↗

Genomic deletions explain the generation of alternative BRAF isoforms conferring resistance to MAPK inhibitors in melanomaSemantic proximity Read ↗

Clinical significance of intronic variants in BRAF inhibitor resistant melanomas with altered BRAF transcript splicingSemantic proximity Read ↗

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutatedSemantic proximity Read ↗

Differential responsiveness to BRAF inhibitors of melanoma cell lines BRAF V600E-mutated.Semantic proximity Read ↗

RNA Editing Signatures Predict Response to Immunotherapies in Melanoma PatientsSemantic proximity Read ↗

BRAFV600E remodels the melanocyte transcriptome and induces BANCR to regulate melanoma cell migration.Semantic proximity Read ↗

Transcriptome-wide decoding the roles of aberrant splicing in melanoma MAPK-targeted resistance evolutionSemantic proximity Read ↗

miR-410-3p is induced by vemurafenib via ER stress and contributes to resistance to BRAF inhibitor in melanomaSemantic proximity Read ↗

Identification of pathways modulating Vemurafenib resistance in melanoma cells via a genome-wide CRISPR/Cas9 screenSemantic proximity Read ↗

Analysis of Amino Acid Variants in Malignant Melanoma Cells Resistant to BRAF inhibitionSemantic proximity Read ↗

Transcriptional landscape in <i>BRAF</i> wild type metastatic melanomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.